Biomarkers in Prostate Cancer: Current and Future

Speaker: Joaquin Mateo

In this video besides elaborating where do we stand in term of response biomarkers as a path to more precise clinical decision-making in prostate cancer, Joaquin Mateo discusses how could proteomics and Genomics accelerate the development of biomarkers in prostate cancer, what role do immune regulation and immuno-biomarkers have in prostate cancer and the future outlook for biomarkers in prostate cancer field. 

In this video besides elaborating where do we stand in term of response biomarkers as a path to more precise clinical decision-making in prostate cancer, Joaquin Mateo discusses how could proteomics and Genomics accelerate the development of biomarkers in prostate cancer, what role do immune regulation and immuno-biomarkers have in prostate cancer and the future outlook for biomarkers in prostate cancer field.

At present, there is no Biomarker that has passed through qualification steps to be incorporated in the standard clinical practice for prostate cancer. However, it is an area of research that is raising a lot of interest and expectations.

There is a lot of ongoing work on how androgen receptor (AR) signalling may stratify patients for standard therapies and how AR Mutations, copy number changes and structural rearrangements can help in identification of patients who benefit from abiraterone and enzalutamide.

Many groups are currently working on how biomarkers can predict benefit from novel therapies and accelerate drug development, e.g. how DNA repair defect can identify prostate cancer patients who have benefit from PARP inhibitors or platinum chemotherapy.